Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas.

Trial Profile

Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Acoustic neuroma; Haemangioblastoma; Meningioma; Neurilemmoma; Neurofibromatosis 2
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Feb 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018 as reported by ClinicalTrials.gov.
    • 26 Feb 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top